KRN 8602

Drug Profile

KRN 8602

Alternative Names: MX 2; NSC 619003

Latest Information Update: 11 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin Brewery
  • Developer Kirin Holdings Company
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Brain cancer; Breast cancer; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 17 Feb 2000 A clinical study in glioma has been added to the therapeutic trials section
  • 25 Aug 1999 A study has been added to the therapeutic trials and adverse events sections
  • 26 Jul 1999 Phase-II clinical trials for Acute lymphoblastic leukaemia in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top